Quarterly ResultApr 13, 2026, 06:59 PM
Biomerica Reports Q3 FY26 Results: European Revenue Up 45%
AI Summary
Biomerica reported its Q3 fiscal 2026 financial results, highlighting significant operational achievements. European revenue surged 45% year-over-year to $287,000, driven by commercial momentum and the UK regulatory registration and first commercial order for hp+detect . The company also announced a national Medicare payment rate of $300 for its inFoods IBS test and a 24% reduction in R&D expenses year-to-date, reflecting a strategic shift towards commercialization.
Key Highlights
- European revenue grew 45% YoY to $287,000 in Q3.
- CMS set $300 national Medicare payment rate for inFoods IBS.
- inFoods IBS showed 59.4% pain reduction, 68.1% bloating reduction.
- R&D expenses decreased 24% YTD to $583,000.
- Over-the-Counter revenue increased 16% YoY in Q3.